BenevolentAI is the global leader in the development and application of artificial intelligence (“AI”) for scientific innovation. It is the largest private AI company in Europe and one of the five largest private AI companies in the world.
BenevolentAI has built a leading position in artificial intelligence by developing technologies that deliver previously unimaginable scientific advances, rapidly accelerate scientific innovation and completely disrupt traditional methods of scientific discovery. The technology has been validated in drug discovery, specifically, in the most challenging field of human biology: the identification of new disease targets.
By amplifying a researchers’ ability to grasp an entire corpus of data and iterate the scientific method at exponentially faster rates, BenevolentAI brings highly advanced tools to traditional R&D programmes enabling artificial intelligence to be applied to the scientific discovery process.
Twitter handle: @benevolent_ai